Business Wire

Industrial Transformation Takes Center Stage at Cognite’s Global “Ignite Talks” October 27-29

6.10.2020 14:00:00 EEST | Business Wire | Press release

Share

Cognite, a leader in industrial innovation, will host its third annual global conference “Ignite Talks: Industrial Intelligence Augmented: Reimagining How Minds and Machines Work Together” from Oct. 27-29, 2020. The free virtual event will feature global leaders and innovators who are driving industries and supply chains toward a more innovative, data-driven, sustainable future.

“The world is at a technological, economic, and environmental crossroads like never before, and we are looking forward to discussing pressing issues among some of the industry’s best,” said John Markus Lervik, Cognite CEO.

The full agenda for this free online conference can be found here and at www.cogniteignite.com.

Day-by-day overviews and panel highlights are listed below:

October 27: Igniting Industrial Transformation: Europe & Norway’s Leading Role

Opening day spotlights how leaders in Europe are melding minds and machines, and inspiring a transformation of heavy-asset industries and supply chains. Panel highlights:

  • What's Next for the Global Energy Transition: The energy transition is here. Can the oil and gas industry adapt, or is it the end of the industry as we know it?
    • Speakers: Bernard Looney, CEO, BP; Ahmad A. Al-Sa’adi, SVP of Technical Services, Saudi Aramco; Øyvind Eriksen, President and CEO, Aker ASA
  • Reinventing Industrial Supply Chains Post-COVID Through Digital Innovation: 2020 has presented the world with a chance to rethink global supply chains. How do we seize the opportunity?
    • Speakers: Sameer Kalra, President Marine Division, Alfa Laval; Victoria Van Camp, CTO, SKF

October 28: America’s Industrial Transformation

The technology prowess of the United States and raw innovative capacity is unmatched, and its heavy-asset industries are taking steps to leverage technology at scale in order to jump-start digital transformations. What will it take to succeed, what role does technology play? Panel highlights:

  • America’s Energy Transition - in partnership with Axios: A live, virtual event, featuring in-depth 1:1 discussions with industry leaders and policymakers on the development of renewable energy in the US, how the coronavirus pandemic has affected energy patterns, and what’s next for the US oil & gas industry. This panel will be hosted by Axios energy and climate change reporter Amy Harder.
  • Industry Under Siege: A New Era of Industrial Cybersecurity: Sophisticated cybercriminals are setting their sights on industry. How can industrial companies digitalize operations while minimizing risk?
    • Speakers: Ron Brash, Director of Cyber Security Insights, Verve Industrial Protection; Tomomi Aoyama, Head of Business Development UK, Nihon Cyber Defence
  • Navigating the Digital Transition to Renewable Energy
    • Speakers: Ashtad Engineer, VP Digital & Transformation, Adani; Astrid Skarheim Onsum, CEO, Aker Offshore Wind

October 29: Driving a Global Transformation from the Bottom Up

The domains and technologies behind the scenes are the real drivers of industrial transformation. The final day gives an insider's view into technology adoption, empowering users with data and domain-specific insights into subsurface and exploration, detection and warning, ocean data, sustainability, and more. Panel highlights:

  • Operationalize and Scale Models and Applications with Trusted Industrial Data: Data issues are still holding back digitalization initiatives. Experts from Forrester and Wintershall Dea explain how to break down barriers and generate meaningful ROI.
    • Speakers: Patrick von Pattay, VP of Intelligent Operations, Wintershall DEA; Paul Miller, Principal Analyst, Forrester
  • Cleaning Up Our Act: Data-Driven Sustainability in Upstream Oil & Gas: Reducing emissions has become the responsibility of every oil and gas company. BP explains how digitalization is powering its sustainable transformation.
    • Speaker: Rob Kelly, Head of Upstream Digital, BP
  • Waves of Change: Using Data to Advance Ocean Sustainability: The oceans are under siege. In this session, leading ocean experts explain how industry can use data to turn the tide.
    • Speakers: Craig McLean, Assistant Administrator of Oceanic and Atmospheric Research, National Oceanic and Atmospheric Administration; Bjørn Tore Markussen, CEO at Center for the 4th Industrial Revolution for the Ocean

About Cognite

Cognite is a global industrial software-as-a-service (SaaS) company supporting the full-scale digital transformation of heavy-asset industries around the world. Their key product, Cognite Data Fusion (CDF), empowers companies with contextualized OT/IT data to drive industrial applications that increase safety, sustainability, and efficiency, and drive revenue. Visit us at www.cognite.com and follow us on Twitter @CogniteData or at LinkedIn: https://www.linkedin.com/company/cognitedata

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Michelle Holford
Global PR Lead - Cognite
+15127443420 (US)
+4748290454 (Norway)
michelle.holford@cognite.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 13:38:00 EEST | Press release

For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will

Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 12:48:00 EEST | Press release

Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye